pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Summit, USA HQ
2,104 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
Celgene patents
0 pharmaceutical patents indexed for Celgene. 0 expire within 24 months.
Celgene has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Celgene have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Celgene patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.